116 related articles for article (PubMed ID: 36827534)
1. Recommendation of mHAP and ABCR scoring systems for the decision-making of the first and subsequent TACE session in HCC patients.
Jia K; Yin W; Gao Z; Shen W; Wang F; Xie S; Li M; Lv R
Eur J Gastroenterol Hepatol; 2023 Apr; 35(4):461-470. PubMed ID: 36827534
[TBL] [Abstract][Full Text] [Related]
2. Validation and evaluation of clinical prediction systems for first and repeated transarterial chemoembolization in unresectable hepatocellular carcinoma: A Chinese multicenter retrospective study.
Wang ZX; Wang EX; Bai W; Xia DD; Mu W; Li J; Yang QY; Huang M; Xu GH; Sun JH; Li HL; Zhao H; Wu JB; Yang SF; Li JP; Li ZX; Zhang CQ; Zhu XL; Zheng YB; Wang QH; Li J; Yuan J; Li XM; Niu J; Yin ZX; Xia JL; Fan DM; Han GH; On Behalf Of China Hcc-Tace Study Group
World J Gastroenterol; 2020 Feb; 26(6):657-669. PubMed ID: 32103874
[TBL] [Abstract][Full Text] [Related]
3. ASARA, a prediction model based on Child-Pugh class in hepatocellular carcinoma patients undergoing transarterial chemoembolization.
Jia KF; Wang H; Yu CL; Yin WL; Zhang XD; Wang F; Sun C; Shen W
Hepatobiliary Pancreat Dis Int; 2023 Oct; 22(5):490-497. PubMed ID: 35260337
[TBL] [Abstract][Full Text] [Related]
4. Validation and prognostic value of EZ-ALBI score in patients with intermediate-stage hepatocellular carcinoma treated with trans-arterial chemoembolization.
Ananchuensook P; Sriphoosanaphan S; Suksawatamnauy S; Siripon N; Pinjaroen N; Geratikornsupuk N; Kerr SJ; Thanapirom K; Komolmit P
BMC Gastroenterol; 2022 Jun; 22(1):295. PubMed ID: 35701739
[TBL] [Abstract][Full Text] [Related]
5. Feasibility of dynamic risk assessment for patients with repeated trans-arterial chemoembolization for hepatocellular carcinoma.
Park Y; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Yeon JE; Byun KS; Kim HS; Kim JH; Kim SU
BMC Cancer; 2019 Apr; 19(1):363. PubMed ID: 30991968
[TBL] [Abstract][Full Text] [Related]
6. Addition of tumor multiplicity improves the prognostic performance of the hepatoma arterial-embolization prognostic score.
Park Y; Kim SU; Kim BK; Park JY; Kim DY; Ahn SH; Park YE; Park JH; Lee YI; Yun HR; Han KH
Liver Int; 2016 Jan; 36(1):100-7. PubMed ID: 26013186
[TBL] [Abstract][Full Text] [Related]
7. Validation of Clinical Scoring Systems ART and ABCR after Transarterial Chemoembolization of Hepatocellular Carcinoma.
Kloeckner R; Pitton MB; Dueber C; Schmidtmann I; Galle PR; Koch S; Wörns MA; Weinmann A
J Vasc Interv Radiol; 2017 Jan; 28(1):94-102. PubMed ID: 27562621
[TBL] [Abstract][Full Text] [Related]
8. Predictive performance of the mHAP-II score in a real-life western cohort with hepatocellular carcinoma following trans-arterial chemoembolisation with drug-eluting beads (DEB-TACE).
Peisen F; Maurer M; Grosse U; Nikolaou K; Syha R; Ketelsen D; Artzner C; Bitzer M; Horger M; Grözinger G
Eur Radiol; 2020 Jul; 30(7):3782-3792. PubMed ID: 32125515
[TBL] [Abstract][Full Text] [Related]
9. Retreatment with TACE: the ABCR SCORE, an aid to the decision-making process.
Adhoute X; Penaranda G; Naude S; Raoul JL; Perrier H; Bayle O; Monnet O; Beaurain P; Bazin C; Pol B; Folgoc GL; Castellani P; Bronowicki JP; Bourlière M
J Hepatol; 2015 Apr; 62(4):855-62. PubMed ID: 25463541
[TBL] [Abstract][Full Text] [Related]
10. A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma.
Lee IC; Hung YW; Liu CA; Lee RC; Su CW; Huo TI; Li CP; Chao Y; Lin HC; Hou MC; Huang YH
Liver Int; 2019 Sep; 39(9):1704-1712. PubMed ID: 31319016
[TBL] [Abstract][Full Text] [Related]
11. Validation of the ALBI-TAE model and comparison of seven scoring systems for predicting survival outcome in patients with intermediate-stage hepatocellular carcinoma undergoing chemoembolization.
Bannangkoon K; Hongsakul K; Tubtawee T
Cancer Imaging; 2023 May; 23(1):51. PubMed ID: 37248526
[TBL] [Abstract][Full Text] [Related]
12. The "Six-and-Twelve" Score for Recurrent HCC Patients Receiving TACE: Does it Still Work?
Ji J; Gu J; Wu JZ; Yang W; Shi HB; Liu S; Zhou WZ
Cardiovasc Intervent Radiol; 2021 May; 44(5):720-727. PubMed ID: 33655358
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of models to predict prognosis in patients with advanced hepatocellular carcinoma treated with TACE combined with apatinib.
Sun F; Liu KC; Ul Ain Q; Lu D; Zhou CZ; Xiao JK; Zhang XM; Zhang ZF; Cheng DL; He YS; Lv WF
BMC Gastroenterol; 2024 Apr; 24(1):129. PubMed ID: 38589828
[TBL] [Abstract][Full Text] [Related]
14. Simple Scoring System for Predicting TACE Unsuitable among Intermediate-Stage Hepatocellular Carcinoma Patients in the Multiple Systemic Treatment Era.
Hiraoka A; Kumada T; Kariyama K; Toyoda H; Yasuda S; Tsuji K; Hatanaka T; Kakizaki S; Naganuma A; Ishikawa T; Tada T; Takaguchi K; Itobayashi E; Shimada N; Shibata H; Tanaka T; Tsutsui A; Nagano T; Imai M; Nakamura S; Nouso K
Oncology; 2022; 100(2):65-73. PubMed ID: 34844247
[TBL] [Abstract][Full Text] [Related]
15. Validation of the six-and-twelve criteria among patients with hepatocellular carcinoma and performance score 1 receiving transarterial chemoembolization.
Wang ZX; Li J; Wang EX; Xia DD; Bai W; Wang QH; Yuan J; Li XM; Niu J; Yin ZX; Xia JL; Fan DM; Han GH
World J Gastroenterol; 2020 Apr; 26(15):1805-1819. PubMed ID: 32351295
[TBL] [Abstract][Full Text] [Related]
16. Cancer of the Liver Italian Program score helps identify potential candidates for transarterial chemoembolization in patients with Barcelona Clinic Liver Cancer stage C.
Li L; Gou CY; Li JY; Achakzai R; Li XH
Hepatobiliary Pancreat Dis Int; 2016 Apr; 15(2):152-7. PubMed ID: 27020631
[TBL] [Abstract][Full Text] [Related]
17. Transarterial chemoembolization for hepatocellular carcinoma: development and external validation of the Munich-TACE score.
Op den Winkel M; Nagel D; Op den Winkel P; Trojan J; Paprottka PM; Steib CJ; Schmidt L; Göller M; Stieber P; Göhring P; Herbst A; Rentsch M; De Toni EN; Göke B; Gerbes AL; Kolligs FT
Eur J Gastroenterol Hepatol; 2018 Jan; 30(1):44-53. PubMed ID: 29076939
[TBL] [Abstract][Full Text] [Related]
18. Albumin-Bilirubin (ALBI) Grade-Based Nomogram for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.
Ho SY; Hsu CY; Liu PH; Lee RC; Ko CC; Huang YH; Su CW; Hou MC; Huo TI
Dig Dis Sci; 2021 May; 66(5):1730-1738. PubMed ID: 32548811
[TBL] [Abstract][Full Text] [Related]
19. A differential risk assessment and decision model for Transarterial chemoembolization in hepatocellular carcinoma based on hepatic function.
Nam JY; Choe AR; Sinn DH; Lee JH; Kim HY; Yu SJ; Kim YJ; Yoon JH; Lee JM; Chung JW; Choi SY; Lee JK; Baek SY; Lee HA; Kim TH; Yoo K
BMC Cancer; 2020 Jun; 20(1):504. PubMed ID: 32487089
[TBL] [Abstract][Full Text] [Related]
20. A nomogram to predict survival of patients with intermediate-stage hepatocellular carcinoma after transarterial chemoembolization combined with microwave ablation.
Ni JY; Fang ZT; Sun HL; An C; Huang ZM; Zhang TQ; Jiang XY; Chen YT; Xu LF; Huang JH
Eur Radiol; 2020 Apr; 30(4):2377-2390. PubMed ID: 31900694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
